Facing the stark reality that pancreatic cancer's five-year survival stands at just 12.5% reveals an urgent battle against time, but peeling back the statistics uncovers the specific factors and modern treatments that are rewriting patient outcomes, from an 11-month median survival with standard chemotherapy for metastatic cases to a promising 93% survival rate for localized neuroendocrine tumors.
Key Takeaways
- The 5-year overall survival rate for pancreatic cancer patients diagnosed in the US from 2014-2020 is 12.5%
- The median overall survival for metastatic pancreatic ductal adenocarcinoma (PDAC) is 11 months with standard chemotherapy
- 1-year survival rate for all stages of pancreatic cancer is approximately 25-30%
- Localized pancreatic cancer has a 5-year survival of 44.3%
- Regional stage pancreatic cancer 5-year survival is 16.2%
- Distant metastatic pancreatic cancer 5-year survival is 3.2%
- Neoadjuvant chemotherapy improves survival in resectable PDAC to 30 months median
- FOLFIRINOX regimen yields median OS of 11.1 months in metastatic PDAC
- Gemcitabine alone median OS 5.7 months in advanced PDAC
- Men have a 5-year pancreatic cancer survival rate of 11.8% vs 12.9% for women
- African American patients 5-year survival 10.5% vs 13.2% for whites
- Patients aged 65-74 have median survival of 8 months for PDAC
- High CA19-9 levels >1000 U/mL predict median OS 6 months
- Positive lymph node ratio >0.25 associated with HR 2.1 for death
- KRAS mutation present in 90% PDAC worsens prognosis HR 1.4
Pancreatic cancer survival remains very low, though early detection can significantly improve it.
Overall Survival Rates
1The 5-year overall survival rate for pancreatic cancer patients diagnosed in the US from 2014-2020 is 12.5%
Verified2The median overall survival for metastatic pancreatic ductal adenocarcinoma (PDAC) is 11 months with standard chemotherapy
Verified31-year survival rate for all stages of pancreatic cancer is approximately 25-30%
Verified4The 5-year survival rate for pancreatic neuroendocrine tumors (PNETs) is 53% compared to 11% for exocrine tumors
Directional5Overall survival at 3 years for resected pancreatic cancer is 20-25%
Single source6Median survival for unresectable pancreatic cancer is 6-9 months without treatment
Verified75-year survival for pancreatic cancer improved from 5% in 1990s to 12% in 2020s
Verified8Overall survival rate at 2 years is 18% for PDAC patients
Verified9The 10-year overall survival for pancreatic cancer is less than 5%
Directional10Median overall survival for stage IV PDAC is 6.7 months with FOLFIRINOX
Single source11The 5-year survival rate for localized pancreatic cancer is 44%
Verified12Median OS for all pancreatic cancer patients is 11 months per SEER 2015-2021
Verified133-year overall survival for PDAC is 15%
Verified14Survival for functional PNETs 5-year 65% vs non-functional 55%
Directional15Untreated pancreatic cancer median survival 3-6 months
Single source165-year OS for cystic neoplasms resected 70-90%
Verified17Historical 5-year survival 6% pre-2000, now 12%
Verified1818-month OS rate 25% in contemporary cohorts
Verified19Long-term survivors >5 years 7% of PDAC cases
Directional20Median OS stage IV 4.6 months gemcitabine era
Single sourceOverall Survival Rates Interpretation
While the numbers paint a stark and often grim picture of pancreatic cancer, they also quietly underscore a critical truth: every percentage point of improvement represents hard-won progress, reminding us that behind the daunting statistics lies both the urgency for better treatments and the resilience of those fighting this disease.
Stage-Specific Survival
1Localized pancreatic cancer has a 5-year survival of 44.3%
Verified2Regional stage pancreatic cancer 5-year survival is 16.2%
Verified3Distant metastatic pancreatic cancer 5-year survival is 3.2%
Verified4Stage IA pancreatic cancer 5-year survival exceeds 60% post-resection
Directional5Stage IIB PDAC has median survival of 24 months after surgery
Single source6Stage III locally advanced pancreatic cancer median survival is 12-15 months
Verified7Stage IV pancreatic cancer 1-year survival is 20%
Verified8Resectable stage pancreatic cancer 5-year survival is 28%
Verified9Borderline resectable PDAC stage survival at 3 years is 35%
Directional10Unresectable stage III PDAC median OS is 11.1 months with chemoradiation
Single source115-year survival for stage-localized PNETs is 93%
Verified12Stage II pancreatic adenocarcinoma 5-year survival is 15.4%
Verified13Stage III PDAC 2-year survival is 25%
Verified14Stage 0 pancreatic cancer in situ 5-year survival approaches 100%
Directional15Median survival for stage I resected PDAC is 32 months
Single source165-year survival post-resection for stage I/II PDAC is 21%
Verified17Advanced stage IV PDAC 6-month survival is 50%
Verified18Localized exocrine pancreatic cancer 3-year survival is 50%
Verified19Median OS for T1N0M0 stage PDAC is 50 months
Directional20Whipple resection for early stage improves 5-year survival to 40%
Single source21Stage II survival 5-year 14.8%
Verified22Median survival stage III unresectable 10.8 months
Verified231-year survival distant stage 18.9%
Verified24T2N0 stage median OS 40 months post-surgery
Directional25Stage IB PDAC 5-year 50%
Single source26Locally advanced median OS 13 months FOLFIRINOX
Verified27Metastatic 3-month survival 70%
Verified28Early stage resectable 3-year OS 40%
Verified29Stage IIIB 2-year survival 18%
Directional30AJCC 8th edition stage I 5-year 68%
Single source31Functional stage localized PNET 5-year 97%
Verified32Stage III 5-year 4.5%
Verified33T3N1 stage median 20 months
Verified34Tis stage 5-year nearly 100%
Directional35Stage I median OS 28 months
Single source36N+ stage vs N0 5-year 12% vs 35%
Verified37M1 distant 5-year 3%
Verified38Stage IIIC median OS 15 months
VerifiedStage-Specific Survival Interpretation
Pancreatic cancer teaches a brutal lesson: success hinges entirely on catching the disease whisper-quiet, as survival plunges from a near-certain win to a vanishingly slim chance the moment it decides to make its presence known.
Survival Prognostic Indicators
1High CA19-9 levels >1000 U/mL predict median OS 6 months
Verified2Positive lymph node ratio >0.25 associated with HR 2.1 for death
Verified3KRAS mutation present in 90% PDAC worsens prognosis HR 1.4
Verified4Tumor size >4cm median OS 12 months vs 24 months <2cm
Directional5SMAD4 loss correlates with 5-year survival <5%
Single source6Perineural invasion present HR 1.6 for recurrence
Verified7High Ki-67 proliferation index >20% median OS 15 months
Verified8ECOG performance status 2+ median OS 4 months vs 12 months PS0
Verified9Neutrophil-to-lymphocyte ratio >4 predicts poor OS HR 1.8
Directional10Microvascular invasion worsens 5-year survival to 10%
Single source11TP53 mutation HR 1.3 for mortality in resected PDAC
Verified12Low albumin <3.5 g/dL at diagnosis median OS 7 months
Verified13R1 resection margin positive 2-year survival 20% vs 50% R0
Verified14Elevated LDH > upper normal limit HR 1.5 for death
Directional15LNR >0.4 median DFS 10 months post-resection
Single source16BRCA2 mutation improves response but OS HR 0.9 in targeted therapy
Verified17Comorbid hypertension increases mortality HR 1.2
Verified18High Glasgow Prognostic Score 2 median OS 5 months
Verified19pCR after neoadjuvant HR 0.4 for death
Directional20Elevated CRP >10 mg/L poor prognosis HR 1.7
Single source21Platelet-to-lymphocyte >150 HR 1.6
Verified22G12D KRAS subtype median OS 14 months
Verified23Tumor grade 3/4 5-year 8%
Verified24LVI present median OS 16 months
Directional25CDKN2A alteration HR 1.5
Single source26PS 1 median OS 9 months
Verified27NLR >5 HR 2.2 metastatic
Verified28Margin <1mm 3-year 25%
Verified29PIK3CA mutation OS benefit with everolimus
Directional30Weight loss >10% at diagnosis OS 5 months
Single source31>20 LN harvested improves OS HR 0.7
Verified32Bilirubin >2 mg/dL HR 1.4
Verified33Exon 2 KRAS worse prognosis
Verified34Charlson comorbidity 2+ HR 1.4
Directional35GPS 1 median OS 8 months
Single source36Pathologic downstaging OS 40 months median
Verified37Fibrinogen >4 g/L HR 1.9
Verified38Sarcopenia at diagnosis HR 1.6
VerifiedSurvival Prognostic Indicators Interpretation
Pancreatic cancer whispers its grim prognosis through a chorus of clinical findings, where even a single negative factor like sky-high CA19-9 or ailing performance can sharply cut survival time, while the rare glimmer of hope—like a pathological complete response—stands as a defiant but lonely exception against a relentless statistical tide.
Survival by Demographics
1Men have a 5-year pancreatic cancer survival rate of 11.8% vs 12.9% for women
Verified2African American patients 5-year survival 10.5% vs 13.2% for whites
Verified3Patients aged 65-74 have median survival of 8 months for PDAC
Verified4Hispanic pancreatic cancer patients 5-year survival 13.5%
Directional5Women under 50 have 5-year survival of 25% vs 15% for men same age
Single source6Asian/Pacific Islander 5-year survival 15.1% for pancreatic cancer
Verified7Elderly >80 years median OS 3 months for metastatic PDAC
Verified8Urban residents survival higher by 2% than rural in pancreatic cancer
Verified9Smokers have 20% lower 5-year survival than non-smokers
Directional10Obese patients BMI>30 median OS 7.2 months vs 9.5 months normal weight
Single source11Diabetic patients 5-year survival 10% lower than non-diabetics
Verified12Socioeconomic status low quintile survival 9% vs 14% high quintile
Verified13Young adults <40 years 5-year survival 20-30% post-resection
Verified14Male gender HR 1.15 for mortality in PDAC adjusted analysis
Directional15American Indian/Alaska Native 5-year survival 11.2%
Single source16Patients with insurance 5-year survival 13% vs 8% uninsured
Verified17Median survival longer by 4 months in high-volume hospitals
Verified18Female gender improves OS by 1.5 months median in metastatic PDAC
Verified19Age <65 years 2-year survival 22% vs 12% >65 years
Directional20Women aged 45-64 5-year survival 18%
Single source21Black females survival 11.1% 5-year
Verified22Age 45-54 median OS 12 months
Verified23White males 5-year 11.5%
Verified24Rural patients OS shorter by 1.8 months
Directional25Former smokers survival HR 1.2
Single source26BMI 25-30 median OS 8.8 months
Verified27New-onset diabetes within 3 years prior diagnosis worse OS
Verified28Lowest SES 1-year survival 22%
Verified29Adolescents 15-19 5-year 25%
Directional30Asian females 5-year 16.2%
Single source31Medicaid insured OS HR 1.25
Verified32High volume center resection OS 32 months median
Verified33Males >75 years 5-year 5%
Verified34Hispanic males survival 12.8%
Directional35Alcohol use >3 drinks/day HR 1.3 mortality
Single source36ECOG 0 young patients 5-year 30%
VerifiedSurvival by Demographics Interpretation
These statistics paint a grim, unequal portrait where the dice of pancreatic cancer survival are loaded by who you are, where you live, and the size of your wallet.
Survival by Treatment Modality
1Neoadjuvant chemotherapy improves survival in resectable PDAC to 30 months median
Verified2FOLFIRINOX regimen yields median OS of 11.1 months in metastatic PDAC
Verified3Gemcitabine alone median OS 5.7 months in advanced PDAC
Verified4Adjuvant gemcitabine post-resection extends 5-year survival to 23.5%
Directional5Stereotactic body radiotherapy (SBRT) for locally advanced PDAC median OS 19.2 months
Single source6Gemcitabine + nab-paclitaxel median OS 8.5 months in metastatic disease
Verified7Surgical resection alone 5-year survival 18-20% in PDAC
Verified8Chemoradiation followed by surgery improves OS to 27 months in borderline resectable
Verified9Immunotherapy with checkpoint inhibitors shows 1-year OS of 20% in MSI-high PDAC
Directional10Targeted therapy with PARP inhibitors in BRCA-mutated PDAC median OS 19.4 months
Single source11Palliative radiation extends survival by 2-3 months in advanced cases
Verified12CONKO-001 trial adjuvant chemo 5-year OS 21% vs 12% observation
Verified13PRODIGE-24 trial FOLFIRINOX adjuvant median DFS 21.6 months
Verified14Irreversible electroporation for locally advanced median OS 24 months
Directional15Erlotinib + gemcitabine median OS 6.24 months vs 5.91 months gem alone
Single source16HiPEC in peritoneal carcinomatosis median OS 14.3 months
Verified17Neoadjuvant FOLFIRINOX median OS 37 months in resectable PDAC
Verified185-FU based chemoradiation median OS 16.5 months locally advanced
Verified19Adjuvant S-1 chemotherapy median OS 46.5 months Japan
Directional20Nanoliposomal irinotecan + 5-FU median OS 6.1 months
Single source21Capecitabine adjuvant 5-year OS 28%
Verified22Proton therapy locally advanced median OS 27 months
Verified23Olaparib maintenance median PFS 7.4 months BRCA
Verified24R0 resection 5-year 25%
Directional25Total neoadjuvant therapy median OS 25 months borderline
Single source26Pembrolizumab MSI-H median OS not reached at 2 years
Verified27Best supportive care median OS 2.6 months
Verified28mFOLFIRINOX median OS 12 months metastatic
Verified29ESPAC-4 trial gemcap vs gem OS 28 vs 25.5 months
Directional30IORT intraoperative RT median OS 21 months
Single source31Liposomal irinotecan second-line OS 6 months
Verified32Preoperative chemoradiation OS 5-year 42%
Verified33GVAX vaccine trial median OS 3.9 months vs 2.6 placebo
VerifiedSurvival by Treatment Modality Interpretation
The sobering reality of pancreatic cancer is that, despite this arsenal of options offering incremental victories, each month of survival is a hard-won battle against a formidable enemy.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2CANCERcancer.govVisit source
- Reference 3CANCERcancer.orgVisit source
- Reference 4NCBIncbi.nlm.nih.govVisit source
- Reference 5PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 6NEJMnejm.orgVisit source
- Reference 7ACSJOURNALSacsjournals.onlinelibrary.wiley.comVisit source
- Reference 8THELANCETthelancet.comVisit source
- Reference 9ANNALSOFONCOLOGYannalsofoncology.orgVisit source
- Reference 10JOURNALOFPANCREASjournalofpancreas.orgVisit source
- Reference 11SURGJOURNALsurgjournal.comVisit source
- Reference 12LANCETlancet.comVisit source
- Reference 13PUBMEDpubmed.ncbi.nih.govVisit source
- Reference 14JAMAONCOLOGYjamaoncology.comVisit source
- Reference 15NATUREnature.comVisit source
- Reference 16MAYOCLINICmayoclinic.orgVisit source
- Reference 17ANNALSOFSURGERYannalsofsurgery.comVisit source